26
|
Di Raimondo F, Longo G, Cacciola E, Milone G, Palumbo GA, Cacciola RR, Alessi M, Giustolisi R. A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. Eur J Haematol Suppl 1996; 56:7-11. [PMID: 8599997 DOI: 10.1111/j.1600-0609.1996.tb00286.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The use of recombinant erythropoietin for treatment of anemia in myelodysplastic patients has so far produced poorer results than expected. Most clinical studies have been conducted without any selection of patients. In the present study we report our experience with the use of rhEPO in a population of selected MDS subjects. Only patients affected by refractory anemia according to FAB criteria, without significant WBC and platelets reduction, with normal LDH and short history of disease were eligible for the study and were treated with rhEPO at a dosage of 150 mg/kg three times a week for 2 months. Among the 12 so treated patients, 7 (58.3%) achieved complete remission, 2 partial remission and 3 failed to respond. This high response rate makes more than acceptable the cost/benefit ratio for rhEPO in RA patients and may identify a subgroup of patients that can be treated successfully with rhEPO alone.
Collapse
|
27
|
Milone G, Stagno F, Guglielmo P, Cacciola E, Di Raimondo F, Cacciola RR, Giustolisi R. Cutaneous vasculitis in non Hodgkin's lymphoma. Haematologica 1995; 80:529-31. [PMID: 8647519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Cutaneous vasculitis has been described in association with various hematological malignancies, but it seems to be very uncommon among non Hodgkin's lymphomas (NHL). For this reason no attention has been given to the peculiarity of this rare association. We identified 5 cases of cutaneous vasculitis among 315 NHL patients examined at our Institution from 1984 through 1990 and after the appearance of vasculitis, we observed some heterogeneity in either the degree of activity or in the clinical outcome of the NHL. The onset of cutaneous vasculitis appeared to mark two different clinical patterns: a vasculitis present from diagnosis characterized an indolent course of the neoplasia, while a late-appearing vasculitis was followed by rapid lymphoma progression and short survival.
Collapse
|
28
|
Di Raimondo F, Palumbo GA, Romeo MA, Cacciola E, Milone G, Impera S, Giustolisi R, Cacciola E. In vitro sensitivity of B-CLL cells to fludarabine and interferons. Leuk Lymphoma 1995; 17:449-53. [PMID: 7549836 DOI: 10.3109/10428199509056856] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
In this study we evaluated the cytotoxicity of Fludarabine (FAMP) both alone and in combination with alpha and beta interferon (IFN) against B-cells from patients affected by chronic lymphocytic leukemia (CLL). We used an in vitro colorimetric assay based on the bioreduction of the tetrazolium salt XTT by viable cells. Fludarabine concentrations ranging from 0.03 to 30 microM were tested on cells collected from 22 B-CLL patients. For each fludarabine concentration, 800 I.U. of either alpha or beta IFN were added. Interferon alone did not exert any cytotoxic effect, while Fludarabine showed a strong cytotoxicity against B-CLL cells. The concentration of Fludarabine required to induce a 50% cytotoxicity (IC50) was below 3 microM (the achievable serum level after standard dose in vivo administration) for 19 out of 22 patients. After IFNs supplementation to Fludarabine, it was possible to identify three groups of samples. The first in which IFNs addition did not produce almost any significant change in Fludarabine cytotoxicity (13/22), the second in which there was an improvement in FAMP IC50 (6/22), and finally the third group in which IFNs worsened it (3/22). Stage of disease was the only identified factor accounting for these different results. The second group included samples from 5 patients at stage A and one at stage B, while in the third group all three samples were from patients at stage C. Interferon-alpha and -beta induced the same degree of FAMP IC50 variation.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
MESH Headings
- Aged
- Antigens, CD/biosynthesis
- Antigens, CD/immunology
- Antineoplastic Agents/pharmacology
- Antineoplastic Combined Chemotherapy Protocols/pharmacology
- B-Lymphocytes/drug effects
- B-Lymphocytes/pathology
- Cells, Cultured
- Drug Screening Assays, Antitumor
- Drug Synergism
- Female
- Humans
- Interferon-alpha/pharmacology
- Interferon-beta/pharmacology
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Male
- Middle Aged
- Vidarabine/analogs & derivatives
- Vidarabine/pharmacology
Collapse
|
29
|
Cacciola E, Giustolisi R, Guglielmo P, Cacciola E. Multiple myeloma and renal transplant. Haematologica 1994; 79:73-5. [PMID: 15378953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023] Open
Abstract
Until now, no case of multiple myeloma (MM) had been reported among the B-lymphoproliferative disorders occurring in organ-transplant recipients. The history of a 58-year-old man who developed IgG-kappa MM 31 months after a cadaveric renal transplant is described. A possible relationship between drug-mediated immunosuppression and the development of MM is discussed.
Collapse
|
30
|
Cacciola E, Consoli U, Giustolisi R, Cacciola E. Ascorbic acid deficiency may be a cause of refractoriness to iron-therapy in the treatment of iron-deficiency anemia. Haematologica 1994; 79:96-7. [PMID: 15378958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023] Open
|
31
|
|
32
|
Di Raimondo F, Giustolisi R, Cacciola E, O'Brien S, Kantarjian H, Robertson LB, Keating MJ. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 1993; 11:63-8. [PMID: 8220155 DOI: 10.3109/10428199309054731] [Citation(s) in RCA: 70] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Autoimmune hemolytic anemia (AHA) is a frequent complication of chronic lymphocytic leukemia (CLL). Although the pathogenesis of AHA is still unknown, an imbalance of normal residual T cells is believed to play a central role. Since fludarabine is reported to affect primarily T lymphocytes, we conducted a retrospective study to evaluate the incidence and outcome of AHA in 112 CLL patients treated with fludarabine alone. Eight patients had AHA before therapy; only one achieved remission of both CLL and AHA after fludarabine alone. In the other seven patients, we observed no effect or even a worsening of AHA, although the CLL was responding to fludarabine. Five patients developed AHA from 1 to 19 months after fludarabine therapy while the CLL was responding. One additional patient developed pure red cell aplasia (PRCA) 3 months after starting therapy. Most patients in both groups responded to steroids or other immunosuppressive therapy. The study showed that in these patients, AHA evolved independently of CLL and was not affected by fludarabine.
Collapse
MESH Headings
- Aged
- Anemia, Hemolytic, Autoimmune/drug therapy
- Anemia, Hemolytic, Autoimmune/etiology
- CD4-CD8 Ratio
- Coombs Test
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/complications
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Male
- Middle Aged
- Retrospective Studies
- Vidarabine/analogs & derivatives
- Vidarabine/therapeutic use
Collapse
|
33
|
Milone G, Guglielmo P, Cacciola E, Calogero D, Giustolisi R. Alpha interferon as first line therapy for angioimmunoblastic lymphoadenopathy. Possible value of DR+ cells in monitoring therapeutical response. Haematologica 1992; 77:524-5. [PMID: 1289192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
|
34
|
Giordano R, Costantini S, Vernillo I, Moramarco A, Rasi V, Giustolisi R, Gabrieli C. Calcium, potassium, zinc, and copper determinations in cataractous human lenses. Microchem J 1992. [DOI: 10.1016/0026-265x(92)90036-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
35
|
Balacco Gabrieli C, Rasi V, Moramarco A, Giustolisi R, Costantini S, Giordano R. Potassium, calcium, copper, zinc and selenium determination in cataractous human lenses. Exp Eye Res 1992. [DOI: 10.1016/0014-4835(92)90857-o] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
36
|
Di Raimondo F, Murolo D, Milone G, Cacciola E, Giustolisi R. Early response to alpha interferon in a patient affected by hairy cell leukemia. Haematologica 1992; 77:355-6. [PMID: 1427445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
A 61-year-old splenectomized male patient affected by hairy cell leukemia (HCL) in relapse was treated with interferon (IFN) at a dosage of 3 x 10(6) U/day. After only 11 days of treatment, IFN was stopped because the patient developed fever, jaundice and respiratory distress. Upon recovery from this infectious episode, the patient was judged to be in complete remission of HCL on the basis of clinical and laboratory findings, and he remained off-therapy for 2 years. When an overt relapse occurred, the patient was again treated with IFN and, after a very short time, he achieved a new, good partial remission that is maintained 28 months later without treatment. This observation remains speculative for understanding the mechanism of action of IFN in other comparable HCL cases.
Collapse
|
37
|
Milone G, Di Raimondo F, Russo M, Cacciola E, Giustolisi R. Unusual onset of severe varicella in adult immunocompromised patients. Ann Hematol 1992; 64:155-6. [PMID: 1533315 DOI: 10.1007/bf01697404] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Abdominal and back pain has until now been reported as a first sign of severe varicella in immunocompromised children only. We report two adult leukemia patients in whom these symptoms preceded visceral dissemination of varicella infection. Recognizing that this syndrome may occur in adult patients is of clinical importance, since it allows early diagnosis and treatment of the infection.
Collapse
|
38
|
Cacciola E, Giustolisi R, Guglielmo P, Di Raimondo F, Cacciola E, Calogero RD. Recombinant interferon alpha in the treatment of polycythemia vera. Blood 1991; 77:2790-1. [PMID: 2043773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
|
39
|
Cacciola E, Giustolisi R, Gugliemo P, Sciacca S, Marra G, Cacciola RR. Persistent generalized lymphadenopathy (transfusion-related) in an HIV-seropositive heterosexual man with sickle-cell beta-thalassemia. Eur J Haematol 1990; 45:116-7. [PMID: 2209816 DOI: 10.1111/j.1600-0609.1990.tb00432.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
40
|
Cacciola E, Musso R, Giustolisi R, Cacciola E, Alessi M. Blood hypercoagulability as a risk factor for leg ulcers in sickle cell disease. Blood 1990; 75:2467-8. [PMID: 2350585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
|
41
|
Giustolisi R, Musso R, Cacciola E. [Antithrombin III and congenital hemolytic anemia]. Haematologica 1990; 75 Suppl 2:54-63. [PMID: 2387552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
|
42
|
Cacciola E, Giustolisi R, Musso R, Longo A, Cacciola E. Antithrombin III concentrate for treatment of chronic leg ulcers in sickle cell-beta thalassemia: a pilot study. Ann Intern Med 1989; 111:534-6. [PMID: 2774375 DOI: 10.7326/0003-4819-111-6-534] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
|
43
|
Musso R, Longo A, Cacciola RR, Lombardo A, Giustolisi R, Cacciola E. Elevated fibronectin plasma levels in diabetes mellitus are expression of increased synthesis and release by vascular endothelium. Thromb Haemost 1989; 61:150-1. [PMID: 2749588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
44
|
Sammartino R, Musso R, Morrone ML, Terranova M, Cavallaro C, Giustolisi R. [Oral surgery in patients with coagulation disorders and hemophilia]. STOMATOLOGIA MEDITERRANEA : SM 1988; 8:165-70. [PMID: 2978488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
45
|
Musso R, Longo A, Triolo A, Giustolisi R, Cacciola RR, Cacciola E, Vecchio R, Russo A, Magnano A. Polidocanol may directly activate the contact phase of blood coagulation during sclerotherapy. Gastrointest Endosc 1987; 33:400-2. [PMID: 3678776 DOI: 10.1016/s0016-5107(87)71661-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
46
|
Guglielmo P, Cunsolo F, Milone G, Di Raimondo F, Giustolisi R, Cacciola E. Cytoplasmic heavy and light chain isotypic suppression by peripheral Fc gamma + T-cells from multiple myeloma. Haematologica 1987; 72:465-8. [PMID: 2961667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
|
47
|
Musso R, Giustolisi R, Cacciola E. Factor VIII-related antigen and ischemic heart disease. Am J Clin Pathol 1987; 88:392-3. [PMID: 3115084 DOI: 10.1093/ajcp/88.3.392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
|
48
|
Musso R, Giustolisi R, Cacciola E. Acute respiratory distress during sclerotherapy for esophageal varices. Ann Intern Med 1987; 106:640. [PMID: 3826974 DOI: 10.7326/0003-4819-106-4-640_1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
|
49
|
Cacciola E, Giustolisi R, Musso R, Vecchio R, Longo A, Triolo A, Cacciola RR. Activation of contact phase of blood coagulation can be induced by the sclerosing agent polidocanol: possible additional mechanism of adverse reaction during sclerotherapy. THE JOURNAL OF LABORATORY AND CLINICAL MEDICINE 1987; 109:225-6. [PMID: 3805873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
50
|
Cacciola E, Di Raimondo F, Guglielmo P, Milone G, Giustolisi R. Low-dose cytarabine in myelodysplastic syndromes and acute leukemia. A comment. Acta Haematol 1986; 75:125-6. [PMID: 3090823 DOI: 10.1159/000206103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|